Market Update 12n 6/20: Biotechs Continue to Rally IBB up 1.87% to $305.50; XBI up 1.93% to $75.60 As we have covered biotech ETFs in the past the XBI is one of our core positions for aggressive investors. It outperforms because of equally weighted positions where a big move in several mid or small caps […]
Update-2… 945 am EDT…Biotechs Hold Support IBB up 1.55% to $285 holding support at $280; XBI up 2.99% to $61.95 holding support at $60. Update-1…More Fallout from Mylan (MYL) EpiPen Drug Pricing MYL stock was down over 4% today on news that the EpiPen was mis-classified as a generic drug and that Medicaid was overcharged. […]
Rayno Large Cap Biopharmaceuticals…Part 2…A Stock pickers Market Time to Rebuild Your Portfolio: ABBV, BMY, GILD Below we have summarized selective metrics for large cap biopharmaceutical companies. We began the process of revising and rebalancing our portfolio after the J.P.Morgan Healthcare Conference. Here are some parameters to watch that should help in stock picking: Stock […]
Can the Reversal Hold? IBB Rockets up 2.75% to 285.49 after hitting 52 week low today at 268.52. XBI up 4.22% to $55.09. Notable movers: Large caps: ABBV, ALXN, AMGN, REGN; BIIB down 0.19%, GILD lagging up only 0.72%. Mid-caps all green: ALKS,CLVS,SGEN,VRTX. All Rayno Small caps recover: CRIS,GERN,GLYC etc. ————- Green Screen Across the […]
Update-1 Rayno Recap for week of 11/20/15 IBB up 3.04%, XBI up 1.92%, XLV up 2.82% Notable Small Cap Winners Curis (CRIS) up 4.13%, Fibrocell Sciences (FCSC) up 3.42%, Geron (GERN) up 4.82%, Ignyta (RXDX) up 37.39%, and Ocera Therapeutics (OCRX) up 5.31%. Notable Rayno Dx and Tools Winners Cepheid (CPHD) up 6.45%, Illumina (ILMN) […]
Biotech Innovation Seeks Value Healthcare Costs Mount The Bio Investor Forum has become a go-to meeting for biotech investors and company executives. Although the presenting companies are early stage or smaller cap public companies the attendees are broadly represented in the industry. And the panel sessions on topics such as Venture Capital, Government Policies and […]
General Issues from Bio Investor Forum See BIOtechNow for detailed articles on BIF#15 Biotech executives and investors came with a record 900 attendees to this annual event which presents key issues in the industry and offers a networking forum with 175 presenting companies to meet with potential investors and partners. Energy and enthusiasm abounded despite […]
October 21 Update 9:45a EDT NASDAQ up 0.4% IBB up 1.57% 1:45p EDT Biotech Thrashing Continues-High Fliers Hit Hardest Healthcare stocks remain under attack with the XLV down 1.5% and the IBB down 1.6%.Healthcare is the sector loser down 2% while the Industrials are up slightly. Large cap Biogen (BIIB) is still up 2.5% after […]
Update-1… 3P September 17 after FED Says No Rate Hike-Biotechs Rally NASDAQ up 0.8% after initial surge Apparently biotech stocks are sensitive to interest rate hikes as many analysts have suggested. Biotech companies need a continual inflow of capital and would be sensitive to higher interest rates. An analyst came on CNBC this AM suggesting […]
Update-1 Stealth End of Month Rally Stops Biotech Slide IBB up 3.4% In July and up 1% on Last Day Stocks roared out of the box on Friday but could not hold and ended flat. NASDAQ Up 2.3% for July. Most biotech stocks were green and momentum players came back in to support their favorites: BLUE, JUNO, KITE, […]
PO Box 3701
Manhattan Beach CA 90266
(310) 871-1231
rod@rayno.com
Rod Raynovich is the founder of Raygent Associates, a management consulting firm providing business development and strategic marketing services in the life science and medical device area. He publishes his thoughts and analysis on the biotech industry at www.raygent.com.